AR and neoplasm: Aside from AR signaling, the tumor may eventually adapt to the low levels of androgen resulting from androgen lowering therapeutic strategies, activating alternative mechanisms for activating AR or by bypassing AR, developing into the castration-resistant form of prostate cancer [29,30].